These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 3532959)

  • 1. [Mitoxantrone-containing combination chemotherapy in patients with non-Hodgkin's lymphoma].
    Kimura I; Ohnoshi T; Masaoka T; Sampi K; Namba K
    Gan To Kagaku Ryoho; 1986 Oct; 13(10):3034-9. PubMed ID: 3532959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A comparative study of mitoxantrone and adriamycin in patients with non-Hodgkin's lymphoma: a preliminary result].
    Kimura I; Ohnoshi T; Masaoka T; Sampi K; Namba K
    Gan To Kagaku Ryoho; 1986 Sep; 13(9):2813-9. PubMed ID: 3530138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Salvage chemotherapy of non-Hodgkin's lymphoma with a four-drug combination of mitoxantrone, etoposide, cisplatin and prednisolone (MEPP)].
    Ohnoshi T; Hayashi K; Ueoka H; Yamane T; Ueno K; Murashima M; Tada A; Yoshida M; Kimura I
    Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 1):626-9. PubMed ID: 3827258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage chemotherapy for non-Hodgkin's lymphoma with a combination of mitoxantrone, etoposide, cisplatin, and prednisolone.
    Ohnoshi T; Hayashi K; Ueoka H; Yamane T; Ueno K; Murashima M; Tada A; Yoshida M; Kimura I
    Cancer Treat Rep; 1987 Jun; 71(6):639-41. PubMed ID: 3581103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitoxantrone alone or in combination chemotherapy (VeMP) as second-line treatment in relapsed or refractory poor-prognosis non-Hodgkin's lymphoma. A report of the Non-Hodgkin's Lymphoma Co-operative Study Group (NHLCSG).
    Santini G; Contu A; Porcellini A; Chisesi T; Coser P; Congiu AM; Morandi S; Manna A; Schintu GM; Quaini R
    Haematologica; 1991; 76(6):485-90. PubMed ID: 1820985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of two multi-drug chemotherapy regimens based on mitoxantrone and epirubicin in 44 patients with non-Hodgkin's lymphoma].
    Gao HR
    Zhonghua Zhong Liu Za Zhi; 1991 Jul; 13(4):287-90. PubMed ID: 1806350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A combination chemotherapy of mitoxantrone, etoposide, carboplatin, and prednisolone (MECP) in recurrent or refractory non-Hodgkin's lymphomas].
    Matsuura Y; Nakamura H; Kogure K; Fukazawa M; Okuyama Y; Kawano E; Ishii A; Nishimura M; Hashimoto S; Oh H
    Gan To Kagaku Ryoho; 1994 Feb; 21(2):237-41. PubMed ID: 8311495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's disease.
    Wiernik PH; Dutcher JP; Einzig AI; Sparano J; Frank M; Friedenberg W
    Cancer J Sci Am; 1998; 4(4):254-60. PubMed ID: 9689984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CHOP versus CNOP (N = mitoxantrone) in non-Hodgkin's lymphoma: an interim report comparing efficacy and toxicity.
    Brusamolino E; Bertini M; Guidi S; Vitolo U; Inverardi D; Merante S; Colombo A; Resegotti L; Bernasconi C; Ferrini PR
    Haematologica; 1988; 73(3):217-22. PubMed ID: 3139519
    [No Abstract]   [Full Text] [Related]  

  • 11. [Combination chemotherapy with mitoxantrone, etoposide, vindesine and prednisolone for relapsed or refractory malignant lymphoma: presence of cross-resistance to CHOP therapy].
    Takagi T; Sakai C; Oguro M
    Gan To Kagaku Ryoho; 1992 Jun; 19(6):917-20. PubMed ID: 1605671
    [No Abstract]   [Full Text] [Related]  

  • 12. [Late phase II clinical study of amrubicin hydrochloride, a novel synthetic anthracycline derivative anticancer agent, for malignant lymphoma].
    Akutsu M; Kano Y; Ogawa M; Miura A; Hirano M; Masaoka T; Tatsumi N
    Gan To Kagaku Ryoho; 2001 Nov; 28(12):1867-76. PubMed ID: 11729479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.
    Rigacci L; Carrai V; Nassi L; Alterini R; Longo G; Bernardi F; Bosi A
    Cancer; 2005 Mar; 103(5):970-7. PubMed ID: 15666323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of CHOP versus MEVP (mitoxantrone, etoposide, vindesine, prednisolone) therapy for intermediate-grade and high-grade non-Hodgkin's lymphoma: a prospective randomized study.
    Takagi T; Sampi K; Sawada U; Sakai C; Oguro M
    Int J Hematol; 1993 Jan; 57(1):67-71. PubMed ID: 8477064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas.
    Rohatgi N; LaRocca RV; Bard V; Sethuraman G; Foon KA
    Am J Hematol; 2002 Jul; 70(3):181-5. PubMed ID: 12111762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The treatment of non-Hodgkin's lymphoma with mitoxantrone-containing regimens.
    Sonneveld P
    Semin Oncol; 1995 Feb; 22(1 Suppl 1):29-31. PubMed ID: 7863349
    [No Abstract]   [Full Text] [Related]  

  • 17. Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone).
    Zwick C; Birkmann J; Peter N; Bodenstein H; Fuchs R; Hänel M; Reiser M; Hensel M; Clemens M; Zeynalova S; Ziepert M; Pfreundschuh M;
    Ann Hematol; 2008 Sep; 87(9):717-26. PubMed ID: 18587579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of chemotherapy CHOP vs. CHOP/VIA in the treatment of aggressive non-Hodgkin's lymphoma: a randomized multicenter study of 132 patients. The PETHEMA group. Program for Study and Therapeutics of malignant hemopathies. Spanish Association of Hematology and Hemotherapy].
    López-Guillermo A; García-Conde J; Alvarez-Carmona AM; León P; Maldonado J; Alcalá A; Zubizarreta A; Sancho-Tello R; Carbonell F; Contreras E; Besses C; Hernando A; Fontanillas M; Montserrat E
    Med Clin (Barc); 1998 May; 110(16):601-4. PubMed ID: 9656196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [VNCOP-B (etoposide, mitoxantrone, cyclophosphamide, vincristine, predonisolone, bleomycin) therapy in elderly patients with aggressive non-Hodgkin lymphoma--a study of efficacy and safety, final report].
    Ishii K; Yamamoto Y; Shigeki T; Kitayama H; Hayashi K; Hirose A; Ohta T; Mugitani A; Fujino H; Yagi T; Hirai M; Teshima H; Katsurada T; Urase F; Kitajima H
    Gan To Kagaku Ryoho; 2005 Jan; 32(1):39-44. PubMed ID: 15675580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL).
    Coleman M; Leonard J; Shuster MW; Kaufman TP
    Eur J Haematol Suppl; 2001 Jul; 64():41-5. PubMed ID: 11486401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.